Research identifies clusterin as a predictive biomarker for anti-PD-1 response in gastric cancer, suggesting improved treatment outcomes.
• Clusterin (CLU) is a new negative predictive biomarker for anti-PD-1 immunotherapy of gastric cancer (GC). • CLU is a pivotal regulator of both tumor-intrinsic proliferation and immune evasion in GC. • CLU abrogation in GC enhances the immune response, boosting T-cell killing ability activity and cytokine secretion.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: